What Referring Physicians Need to Know About Current Peripheral Artery Disease Guidelines - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

What Referring Physicians Need to Know About Current Peripheral Artery Disease Guidelines

Peripheral artery disease (PAD) affects millions of Americans, yet many patients remain undiagnosed until symptoms become severe.

  • By

  • June 22, 2026

  • 4 min

Share

Objective:

To inform referring physicians about the current guidelines for the identification and management of peripheral artery disease (PAD).

Approach:
    Key Findings:
    • Many patients with PAD are asymptomatic but still at risk for major cardiovascular events.
    • Risk factors for PAD include age, diabetes, smoking, hypertension, dyslipidemia, chronic kidney disease, family history, and known cardiovascular disease.
    • The ankle-brachial index (ABI) is a key diagnostic tool but has limitations in certain populations.
    • Comprehensive vascular testing provides a more complete assessment of vascular health.
    • PAD is a marker of systemic atherosclerotic disease, necessitating broader cardiovascular risk assessment.
    Interpretation:

    The guidelines serve to enhance the quality of care for PAD patients while emphasizing the importance of clinical judgment.

    Limitations:
    • The article does not provide specific data on the prevalence of undiagnosed PAD.
    • Limitations of the ABI in certain populations are acknowledged but not detailed.
    Conclusion:

    Referring physicians are crucial in the early detection and management of PAD, facilitating access to advanced diagnostics and coordinated care.

    Sources:

Original Source(s)

What Referring Physicians Need to Know About Current Peripheral Artery Disease Guidelines

  • by

  • June 22, 2026

Related Content

FDA Approves First Oral PCSK9 Inhibitor

Merck reported placebo-adjusted LDL-C reductions of 56% and 59% at week 24 in two phase 3 CORALreef trials supporting the approval.

Oral Aleniglipron Reduced Weight at 36 Weeks

In a phase 2b trial, the highest dose produced an estimated 12% mean weight reduction vs 1% with placebo, although gastrointestinal adverse events were common.

AHA: Coffee Need Not Be Avoided in AF

Moderate coffee consumption generally appeared safe for most adults, but randomized evidence suggested divergent effects on atrial fibrillation and premature ventricular contractions.